Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FLT3 exon 14 ins FLT3 N701K |
| Therapy | Azacitidine + Gilteritinib |
| Indication/Tumor Type | acute myeloid leukemia |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 exon 14 ins FLT3 N701K | acute myeloid leukemia | predicted - resistant | Azacitidine + Gilteritinib | Case Reports/Case Series | Actionable | In a clinical case study, FLT3 N701K was identified upon progression with Xospata (gilteritinib) and Vidaza (azacitidine) combination treatment in a patient with relapsed acute myeloid leukemia harboring a FLT3-ITD mutation (PMID: 37815132). | 37815132 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (37815132) | The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib. | Full reference... |